CoChat

Targeted proteomics improves cardiovascular risk prediction in secondary prevention

Open access
Nurmohamed, Nick S., Belo Pereira, João P., Hoogeveen, Renate M., Kroon, Jeffrey, Kraaijenhof, Jordan M., Waissi, Farahnaz, Timmerman, Nathalie, Bom, Michiel J., Hoefer, Imo E., Knaapen, Paul, Catapano, Alberico L., Koenig, Wolfgang, de Kleijn, Dominique, Visseren, Frank L.J., Levin, Evgeni, Stroes, Erik S.G. · 2022 · European Heart Journal
Cited by 144

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Aims: Current risk scores do not accurately identify patients at highest risk of recurrent atherosclerotic cardiovascular disease (ASCVD) in need of more intensive therapeutic interventions. Advances in high-throughput plasma proteomics, analysed with machine learning techniques, may offer new opportunities to further improve risk stratification in these patients. Methods and results: Targeted plasma proteomics was performed in two secondary prevention cohorts: the Second Manifestations of ARTerial disease (SMART) cohort (n = 870) and the Athero-Express cohort (n = 700). The primary outcome was recurrent ASCVD (acute myocardial infarction, ischaemic stroke, and cardiovascular death). Machine learning techniques with extreme gradient boosting were used to construct a protein model in the derivation cohort (SMART), which was validated in the Athero-Express cohort and compared with a clinical risk model. Pathway analysis was performed to identify specific pathways in high and low C-reactive protein (CRP) patient subsets. The protein model outperformed the clinical model in both the derivation cohort [area under the curve (AUC): 0.810 vs. 0.750; P < 0.001] and validation cohort (AUC: 0.801 vs. 0.765; P < 0.001), provided significant net reclassification improvement (0.173 in validation cohort) and was well calibrated. In contrast to a clear interleukin-6 signal in high CRP patients, neutrophil-signalling-related proteins were associated with recurrent ASCVD in low CRP patients. Conclusion: A proteome-based risk model is superior to a clinical risk model in predicting recurrent ASCVD events. Neutrophil-related pathways were found in low CRP patients, implying the presence of a residual inflammatory risk beyond traditional NLRP3 pathways. The observed net reclassification improvement illustrates the potential of proteomics when incorporated in a tailored therapeutic approach in secondary prevention patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac055

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 144

Metadata

Authors
Nurmohamed, N. S., Belo Pereira, J. P., Hoogeveen, R. M., Kroon, J., Kraaijenhof, J. M., Waissi, F., Timmerman, N., Bom, M. J., Hoefer, I. E., Knaapen, P., Catapano, A. L., Koenig, W., de Kleijn, D., Visseren, F. L. J., Levin, E., & Stroes, E. S. G.
Venue
European Heart Journal
Published
2022-02-09
Volume
43
Issue
16
Pages
1569-1577
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4210537932
Cited by
144
References
23
FWCI
23.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted proteomics improves cardiovascular risk prediction in secondary prevention. https://app.cochat.ai/papers/10.1093/eurheartj/ehac055
The paper
Nurmohamed, N. S., Belo Pereira, J. P., Hoogeveen, R. M., Kroon, J., Kraaijenhof, J. M., Waissi, F., Timmerman, N., Bom, M. J., Hoefer, I. E., Knaapen, P., Catapano, A. L., Koenig, W., de Kleijn, D., Visseren, F. L. J., Levin, E., & Stroes, E. S. G. (2022). Targeted proteomics improves cardiovascular risk prediction in secondary prevention. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.